NASDAQSLDB

georgeclerk J.P. Morgan upgraded Solid Biosciences (NASDAQ:SLDB) from neutral to outperform, sending shares of the biotech up 10% Monday. The firm also raised its price target to $15 from $10 (~89% upside based on July 12 close). Analyst Anupam Rama believes that a recent label expansion for Sarepta Therapeutics’ (SRPT)Continue Reading